Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal (PREDESCI)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.
Recruitment status was  Recruiting
Information provided by:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Identifier:
First received: January 28, 2010
Last updated: June 21, 2011
Last verified: June 2011
This is a multicenter, randomized, double-blind, placebo-controlled study on the effectiveness of treatment with beta-blockers to prevent decompensation of cirrhosis with portal hypertension.

Condition Intervention Phase
Portal Hypertension Gastropathy
Esophageal Varices
Spontaneous Bacterial Peritonitis
Hepatic Encephalopathy
Drug: propranolol
Drug: carvedilol
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension

Resource links provided by NLM:

Further study details as provided by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau:

Primary Outcome Measures:
  • Appearance of complications of portal hypertension: bleeding (caused by portal hypertension gastropathy and / or esophageal varices), ascites and / or spontaneous bacterial peritonitis(PBE), hepatic encephalopathy. Death from any cause. [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Compare the appearance of each of the complications of portal hypertension (ascites, SBP and other bacterial infections, varicose veins or signs of high risk, upper gastrointestinal bleeding portal hypertension, hepatic encephalopathy). [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Assess the development of liver failure. [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Quantify the adverse effects of treatment (occurrence and intensity, need to withdraw the treatment). [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • To assess survival. [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 210
Study Start Date: September 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Propranolol Drug: propranolol
GPVH ≥ 10 mmHg - responders: propranolol.
Experimental: carvedilol Drug: carvedilol
GPVH ≥ 10 mmHg nonresponders: carvedilol.
Placebo Comparator: Placebo Drug: placebo
placebo propranolol / carvedilol


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Between 18 and 80 years old.
  • With liver cirrhosis diagnosed by previous biopsy or by clinical criteria, and analytical image.
  • No esophageal varices (or with small varices without red signs) in a recent videogastroscophy (<3 months before randomization).
  • Absence of ascites demonstrated by a recent ultrasound (<3 months before the randomization).
  • informed consent

Exclusion Criteria:

  • previous decompensation of liver cirrhosis associated with portal hypertension.
  • GPVH <10 mmHg.
  • Portal axis thrombosis affecting the portal trunk or main hepatic branches, or the splenic or mesenteric vein.
  • Hepatocellular carcinoma demonstrated by two imaging tests.
  • Bilirubin> 3 mg / dl (or> 50 micromol / l), platelets <30 x10E9/lo Quick <30%.
  • Presence of renal insufficiency (serum creatinine> 2 mg / dl or> 200 micromol / l).
  • Any comorbidity involving a therapeutic limitation and / or a prognosis of life <12 months.
  • Absolute contraindication to treatment with β-blockers (severe bronchospasm, stenosis aortic A-V block, intermittent claudication, severe psychosis, bronchial asthma)
  • Hypersensitivity to β-blockers.
  • Pregnancy or lactation.
  • To receive anticoagulant treatment.
  • Past treatment with nitrated or β-blockers in the two weeks prior inclusion.
  • Cirrhosis C virus active antiviral therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01059396

Contact: Sara Varea + 34 932275400 ext 3343

Hospital German Trias i Pujol Recruiting
Badalona, Spain
Contact: Rosa M Morillas, MD         
Principal Investigator: Rosa M Morillas, MD         
Hospital Clinic i Provincial de Barcelona Recruiting
Barcelona, Spain
Contact: Jaume Bosch, MD   
Principal Investigator: Jaume Bosch, MD         
Hospital de la Santa Creu i Sant Pau Recruiting
Barcelona, Spain
Contact: Càndid Villanueva, MD   
Principal Investigator: Càndid Villanueva, MD         
Hospital de la Vall d'Hebron Recruiting
Barcelona, Spain
Contact: Joan Genescà, MD   
Principal Investigator: Joan Genescà, MD         
Hospital Arnau de Vilanova Recruiting
Lérida, Spain
Contact: Carles Aracil, MD         
Principal Investigator: Carles Aracil, MD         
Clínica Puerta del Hierro Recruiting
Madrid, Spain
Contact: Jose L Calleja, MD         
Principal Investigator: Jose L Calleja, MD         
Hospital Gregorio Marañón Recruiting
Madrid, Spain
Contact: Rafael Bañares, MD         
Principal Investigator: Rafael Bañares, MD         
Hospital Ramón y Cajal Recruiting
Madrid, Spain
Contact: Agustin Albillos, MD         
Principal Investigator: Agustín Albillos, MD         
Sponsors and Collaborators
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Principal Investigator: Càndid Villanueva Sánchez, MD Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
  More Information

Responsible Party: Clinical Trials Unit - Hospital Clínic de Barcelona, CTU Clínic Identifier: NCT01059396     History of Changes
Other Study ID Numbers: PREDESCI 
Study First Received: January 28, 2010
Last Updated: June 21, 2011
Health Authority: Spain: Spanish Agency of Medicines

Additional relevant MeSH terms:
Brain Diseases
Hepatic Encephalopathy
Hypertension, Portal
Brain Diseases, Metabolic
Cardiovascular Diseases
Central Nervous System Diseases
Digestive System Diseases
Hepatic Insufficiency
Intraabdominal Infections
Liver Diseases
Liver Failure
Metabolic Diseases
Nervous System Diseases
Peritoneal Diseases
Vascular Diseases
Adrenergic Agents
Adrenergic Antagonists
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Antihypertensive Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on May 25, 2016